Eli Lilly sues compounding pharmacies and clinics over unapproved retatrutide

Eli Lilly has filed six lawsuits against businesses, including a licensed 503A compounding pharmacy, for distributing unapproved versions of its investigational drug retatrutide. For medical aesthetics clinics, this litigation is a stark warning against sourcing or offering unapproved peptides that sit outside FDA compliance pathways.

The lawsuits, filed on August 13, 2026, target several entities including Aesthetic Envy, Astra LLC, Legendary Peptides, Lone Star Peptides, Striker Pharmacy, LLC, and Texas Peptides. Retatrutide is still an investigational drug. Because it has not received FDA approval for any clinical use, it cannot legally be prepared or distributed under compounding sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act.

This litigation follows more than a dozen warning letters already issued by the FDA over the unlawful distribution of retatrutide. Shabbir Imber Safdar, the Executive Director of the Partnership for Safe Medicines, warned that these activities pose a serious danger to patient safety. He also raised concerns about whether current regulatory enforcement provides a sufficient deterrent when the potential profits are so high.

For practices offering medical weight loss or wellness therapies alongside aesthetic injectables, the legal exposure here is severe. Even if a licensed compounder offers to supply retatrutide, the drug remains entirely unapproved. Clinicians must verify the regulatory status of any peptide therapy they introduce and avoid investigational compounds until they clear official FDA approval channels.

Source: Partnership for Safe Medicines, https://www.safemedicines.org/statement-on-retatrutide-litigation.html